Annual Meeting May 24, 2012. Competitive Technologies, Inc. © 2012 2 Statements made about our future expectations are forward- looking statements and.

Annual MeetingAnnual MeetingMay 24, 2012May 24, 2012

Competitive Technologies, Inc. © 20122

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K/A for the year ended December 31, 2011, filed with the SEC on May 15, 2012, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

Safe Harbor Statement


Funding

Medical Insurance Reimbursement

Sales Growth

Topics to be Discussed


Basis for Optimism - Calmare Works!

Frank Sparadeo, Ph.D.

Doctorate in Clinical Psychology

Private practice since 1983

Worked in hospitals in Massachusetts and Rhode Island

Taught at universities in Massachusetts and Rhode Island

Active in Calmar Pain Relief program since June 2010

Review his study of 250 patients


Board Composition

Board Member Member Since

Peter Brennan June 2011

Richard D. Hornidge February 2007

Rustin Howard October 2007

Robert G. Moussa January 2012

Stan Yarbro, Ph.D. March 2012


Medical Device Corporations vs.CTTC

Robert Moussa, CEO - Dilon Technologies

40 Years in Medical Device Industry:• Chairman, President & CEO, Dilon Technologies

• President, Malinkrodt International

• President & CEO, Malinkrodt Medical

• Sherwood Medical

CTTC Organization Chart



Funding Types

Government Loan

Two year 6% notes convertible at $1.05/share

Sale of common shares


Funding

SBA Loan – One million dollars

Three Investment banking groups

Private Investors


Sales Personnel - Domestic

Commissioned Sales Staff

Challenges have been:

• Reimbursement• Clinical studies• Long lead time for each sale


Sales Personnel - Domestic

Changes Planned

Hire sales employees

Ability to control time and efforts

Evaluate quality of existing commissioned sales

personnel

Increase number commissioned sales personnel


International Sales

Distributor CountryAble Global Healthcare Sdn Bhd Malaysia

Biogene Pharma Limited Bangladesh

Excel Life Sciences, Inc. India

Fintrade Greece, Cyprus

GEOMC Co. Ltd. Korea, Japan

Life Episteme Italia Italy, Malta

The Mediterranean for Technology & Trading SAL Offshore

Lebanon, Turkey, Iraq, Jordan, Oman, Qatar, Bahrain, Kuwait, UAE, Yemen, Saudi Arabia, Mauritania, Morocco, Algeria, Tunisia, Libya, Egypt


Insurance Reimbursement

Obtain Medicare Approval• Hospital – Outpatient – 1 group

• Hospital – Inpatient – 10 groups

• Doctors/Clinics – 10 different groups

Private Carriers• Bottom up – work with doctors/clinics on filing claims

• Top down – work with insurer’s medical directors


SUMMARY

We have a medical device that is needed. Over 100 million people in the U.S. alone spend over $500 billion on pain.

The device works as shown by clinical trials and by Dr. Sparadeo’s research.


SUMMARY

We have new advisory resources on our Board of Directors.

The funding process is in high gear.

With funding, we can push sales and insurance reimbursement.

The international sales program is in place.


SUMMARY

Our objectives are as follows:

Move this technology to the forefront of pain therapy Transform CTTC into a profitable growth company.


THANK YOU!

Competitive Technologies, Inc.www.competitivetech.netwww.calmarett.com

Annual Meeting May 24, 2012. Competitive Technologies, Inc. © 2012 2 Statements made about our future expectations are forward- looking statements and.

Documents